With Voxzogo under pressure, BioMarin touts trial win in label expansion bid

With phase 3 results that have “exceeded” BioMarin’s expectations, according to R&D chief Greg Friberg, M.D., the California biotech appears set up to gain a label expansion for its top-selling | With phase 3 results that have “exceeded” BioMarin’s expectations, the California biotech looks set up to gain a label expansion for its top-selling product, dwarfism drug Voxzogo.